Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
University of California, Los Angeles · Adaptive Biotechnologies (United States) · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,379
total citations
- FWCI
- 100.16
- Percentile
- 100%
- References
- 80
Citations per year
Authors
30Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Neoadjuvant therapy
- Adjuvant
- Oncology
- Immune system
- Immunotherapy
- Blockade
UN Sustainable Development Goals
- No poverty
No related works found for this paper.